efgartigimod alfa and hyaluronidase (human recombinant)

FDA Drug Profile — VYVGART Hytrulo

efgartigimod alfa and hyaluronidase (human recombinant) is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including VYVGART Hytrulo. Available dosage form: injection, solution.

Drug details

Generic Name
efgartigimod alfa and hyaluronidase (human recombinant)
Brand Names
VYVGART Hytrulo
Application Number
BLA761304
Sponsor
Argenx US
NDC Codes
4
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
EFGARTIGIMOD ALFA, HYALURONIDASE (HUMAN RECOMBINANT)

Indications and Usage

1 INDICATIONS AND USAGE VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.